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Summary
 
In vivo manipulation of cytokine and/or cytokine receptor expression has previously shown
that resistance to infection with the caecum-dwelling helminth 
 
Trichuris muris
 
 is dependent on
interleukin (IL)-4 and IL-13 while susceptibility is associated with a T helper cell type 1 (Th1)
cytokine response. Using gene-targeted mice deficient in tumor necrosis factor (TNF) receptor
signaling and anti–TNF-
 
a
 
 monoclonal antibody treatment, we have extended these studies to
reveal a critical role for TNF-
 
a 
 
in regulation of Th2 cytokine–mediated host protection. In
vivo blockade of TNF-
 
a
 
 in normally resistant mice, although not altering IL-4, IL-5, or IL-13
production in the draining lymph node, significantly delayed worm expulsion for the duration
of treatment. IL-13–mediated worm expulsion in IL-4 knockout (KO) mice was also shown to
be TNF-
 
a
 
 dependent, and could be enhanced by administration of recombinant TNF-
 
a
 
. Fur-
thermore, TNF receptor KO mice failed to expel 
 
T
 
.
 
 muris
 
, producing high levels of parasite-
specific immunoglobulin G2a and the generation of a predominantly Th1 response, suggesting
that the absence of TNF function from the onset of infection dramatically alters the phenotype
of the response. These results provide the first demonstration of the role of TNF-
 
a
 
 in regulat-
ing Th2 cytokine–mediated responses at mucosal sites, and have implications for the design of
rational therapies against helminth infection and allergy.
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I
 
nitiation of an appropriate Th response is critical in de-
termining the outcome of infection with the caecum-
dwelling nematode 
 
Trichuris muris
 
. After antigenic stimula-
tion, naive T cells differentiate into distinct Th cell subsets
that produce characteristic cytokine profiles and determine
the nature of the effector response. Th1 cells are defined by
their secretion of IFN-
 
g
 
, IL-2, and lymphotoxin (LT),
 
1
 
and stimulate IgG2a production and cell-mediated effector
responses, while Th2 cells produce IL-4, IL-5, IL-9, and
IL-13 and promote mastocytosis, eosinophilia, and the pro-
duction of IgE and IgG1 (for reviews, see references 1–3).
Inbred mouse strains that naturally mount a Th1 response
are unable to expel 
 
T
 
.
 
 muris
 
 and are susceptible to infection
(4). Induction of a Th2 response in susceptible strains, ei-
ther by blocking IFN-
 
g
 
 or IL-12 production or by the
administration of IL-4 (5; Bancroft, A.J., manuscript in
preparation), converts them to a resistant phenotype. Con-
versely, in mouse strains that are resistant to infection,
administration of IL-12, disruption of the IL-4 gene, or
blockade of the IL-4 receptor (IL-4R) will effectively ab-
late protection (5–7). Similar in vivo manipulations in
other helminth models, including 
 
Heligmosomoides polygyrus
 
and 
 
Nippostrongylus brasiliensis
 
 infections, have identified the
role of Th1 responses in prolonging parasite survival and
Th2 responses in regulation of host protection (8–11; for a
review, see reference 12). A vital and distinct role for IL-13
 
in resistance to 
 
T
 
.
 
 muris
 
 has recently been identified in
IL-13 knockout (KO) mice, which are unable to clear in-
fection despite generating parasite-specific Th2 responses (7).
Although the effector mechanisms operating in 
 
T
 
.
 
 muris
 
infection have yet to be defined, it is clear that IL-4 and
IL-13 regulate immunological and physiological events in
the intestinal mucosa which mediate host protection. Th2
cells are also known to be important in the regulation of
 
1
 
Abbreviations used in this paper:
 
 ES Ag, excretory/secretory antigen; KO,
knockout; LT, lymphotoxin; p.i., postinfection; WT, wild-type. 
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Regulation of Th2 Cytokine Responses by TNF-
 
a
 
mucosal inflammation and exacerbation of disease in mod-
els of airway hyperresponsiveness. Transgenic mice overex-
pressing IL-4 or IL-5 in the lung develop mucus hyper-
secretion and similar pathology to that observed during
allergic asthma (13, 14). IL-13 has also been identified as a
key regulatory cytokine in airway inflammation (15, 16).
Using an OVA-specific TCR transgenic CD4 cell transfer
model, administration of TNF-
 
a
 
 has been shown to en-
hance Th2 cell transendothelial migration and to potentiate
mucosal inflammation in the airway epithelium (17), sug-
gesting that TNF-
 
a
 
 may also be important in mucosal Th2
responses during intestinal helminth infection.
In this study, we have identified a novel role for TNF-
 
a
 
in the downstream regulation of Th2 cytokine effector re-
sponses in the intestinal mucosa. Both in vivo neutraliza-
tion of TNF-
 
a
 
 and use of TNFR-deficient mice have
shown that TNF-
 
a
 
 is critical in regulating host protection
to helminth infection. Blockade of TNF-
 
a
 
 in normally re-
sistant C57BL/6 mice prevents worm expulsion for the du-
ration of treatment despite equivalent Th2 responses in
anti–TNF-
 
a 
 
and control treated mice. In the complete ab-
sence of TNFR signaling, 
 
T
 
.
 
 muris
 
 infection proceeds to
chronicity with the generation of a nonprotective Th1 re-
sponse. Furthermore, IL-13–dependent expulsion in IL-4
KO mice is also impaired during blockade of TNF-
 
a
 
,
whereas clearance of infection is enhanced in these mice by
the administration of recombinant TNF-
 
a
 
. This is the first
study to identify a role for TNF-
 
a
 
 in protection during in-
testinal helminth infection and has important implications
for our understanding of the initiation and regulation of
Th2 effector responses at mucosal sites.
 
Materials and Methods
 
Animals.
 
Mice doubly deficient in both the TNFR p55 and
p75 genes (TNFR KO; from Dr. J. Peschon, Immunex Corp.,
Seattle, WA) were generated as described (18) and maintained as
random C57BL/6 
 
3
 
 129 hybrids at the University of Manches-
ter. Age- and sex-matched C57BL/6 
 
3
 
 129 F
 
2
 
 mice were bred
from F
 
1
 
 littermates (Harlan Olac) and used as wild-type (WT)
controls. BALB/c IL-4 KO mice were generated by Noben-
Trauth et al. (19) and bred at the University of Manchester.
Age- and sex-matched C57BL/6 and BALB/c mice were pur-
chased from Harlan Olac. In all experiments, mice were infected
when 6–9 wk old, and experimental groups contained four to six
animals. All experiments were performed under the regulations of
the Home Office Scientific Procedures Act (1986).
 
Parasites.
 
The maintenance, infection, and recovery of 
 
T
 
.
 
muris
 
 were as described previously (20). Mice were infected on
day 0 with 
 
z
 
200 embryonated eggs, and numbers of larvae were
counted on day 10 postinfection (p.i.) to ensure equivalent estab-
lishment of infection in different groups. Worm burdens were as-
sessed on various days p.i. as described previously (21). 
 
T
 
.
 
 muris
 
excretory/secretory antigen (ES Ag) was prepared as detailed pre-
viously (7).
 
Antibody and Cytokine Reagents.
 
In vivo depletion of TNF-
 
a
 
was carried out using purified rat IgG1 mAb XT22 (neutralizing
TNF-
 
a
 
; from Dr. R. Coffman, DNAX Research Institute, Palo
Alto, CA) injected intraperitoneally as detailed in the text. Con-
trol groups were treated with either isotype-matched control
(GL113; from Dr. F. Finkelman, University of Cincinnati, Cin-
cinnati, OH) or purified rat IgG (Sigma Chemical Co.). Recom-
binant TNF-
 
a
 
 (Dr. G. Luheshi, University of Manchester) was
delivered intraperitoneally as described in the text.
 
Cell Culture and Cytokine Analysis.
 
Mesenteric lymph node
cells were removed from uninfected and infected mice and resus-
pended in RPMI 1640 supplemented with 10% FCS, 2 mM
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin (all
from GIBCO BRL), and 60 
 
m
 
M monothioglycerol (Sigma
Chemical Co.). Cultures were stimulated with a predetermined
optimum concentration of 
 
T
 
.
 
 muris
 
 ES Ag (50 
 
m
 
g/ml) at 37
 
8
 
C
and 5% CO
 
2
 
. Anti–IL-4R (M1) mAb (5 
 
m
 
g/ml; from Dr. C.
Maliszewski, Immunex Corp., Seattle, WA) was added to cul-
tures to increase detection of IL-4. Cell-free supernatants were
harvested after 24 h and stored at 
 
2
 
20
 
8
 
C.
Cytokine analysis was carried out by sandwich ELISA using
paired mAbs to detect IL-4 (BVC4-1D11 and BVD6-24G2.3;
PharMingen), IL-5 (TRFK.5 and TRFK.4; PharMingen), IL-9
(249.2 and biotinylated 1C10/2C12; from Dr. J. van Snick, Lud-
wig Institute of Cancer Research, Brussels,
 
 
 
Belgium), IFN-
 
g
 
(R46A2 and XMG.2; PharMingen), and IL-12 (C15.6 and
C17.8; from Dr. G. Trinchieri, Wistar Institute, Philadelphia,
PA). TNF-
 
a
 
 and IL-13 production was assessed using an R&D
Systems ELISA kit. Quantification of cytokines was determined
by reference to commercially available recombinant murine stan-
dards, and the sensitivity of the assays was determined by taking
the mean 
 
1 
 
3 SD of 16 control wells containing medium alone.
 
Antibody Analysis.
 
Analysis of parasite-specific IgG1 and
IgG2a production was carried out by capture ELISA as described
(22). In brief, Immulon IV plates (Dynatech) were coated with 
 
T
 
.
 
muris
 
 ES Ag (5 
 
m
 
g/ml) in carbonate/bicarbonate buffer, pH 9.6,
overnight at 4
 
8
 
C. After blocking (3% BSA in PBS, 0.05% Tween),
eight serial 2-fold dilutions of sera (from an initial 20-fold dilu-
tion) were added to the plates. Parasite-specific antibody was de-
tected using biotinylated rat anti–mouse IgG1 (Serotec Ltd.) and
biotinylated rat anti–mouse IgG2a (PharMingen).
 
Statistics.
 
Significant differences (
 
P
 
 , 
 
0.05) between experi-
mental groups were determined using the Mann-Whitney U test.
 
Results
 
In Vivo Blockade of TNF-
 
a
 
 in C57BL/6 Mice Prevents
Worm Expulsion.
 
We have previously demonstrated that
C57BL/6 mice mount Th2 responses and expel 
 
T
 
.
 
 muris
 
(7). The role of TNF-
 
a
 
 in regulating this host protection
was investigated by administering 2 mg of anti–TNF-
 
a
 
 or
control antibody (GL113) intraperitoneally every 3 d be-
tween days 7 and 19 p.i. Blockade of TNF-
 
a
 
 significantly
prevented worm expulsion at day 21 p.i. compared with
control treated groups (Fig. 1 A). With the exception of
depressing IL-9 production, anti–TNF-
 
a
 
 treatment did not
significantly alter the magnitude of the Th2 response gen-
erated at day 21 p.i. (Fig. 2).
Prevention of worm expulsion is transient, and cessation
of anti–TNF-
 
a
 
 treatment resulted in the clearance of infec-
tion in all treatment groups by day 35 p.i. (Fig. 1 B). As the
cytokine response has diminished by day 35 p.i. (data not
shown), this suggests that a sufficient Th2 response was
generated in the mesenteric lymph nodes of anti–TNF-
 
a
 
treated mice to induce worm expulsion (Fig. 2). Therefore,
although depletion of TNF-
 
a
 
 has no demonstrable effect 
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on the initiation of Th2 responses, it appears to be critical
in the regulation of Th2 cell effector function in the intes-
tine. This hypothesis is reinforced by the parasite-specific
IgG isotype response at day 35 p.i. Expulsion of 
 
T
 
.
 
 muris
 
occurs in the absence of antibody (23); however, assess-
ment of IgG isotype production provides an indication of
the polarization of the Th response after infection. IgG1
production is known to be under the control of Th2 cy-
tokines (24), and there was no significant difference in this
response between treatment groups (Fig. 3 A), substantiat-
ing the fact that there is no reduction in the magnitude of
the Th2 response after anti–TNF-
 
a
 
 treatment. The ele-
vated IgG2a response (under the control of IFN-
 
g
 
 [25])
observed after blockade of TNF-
 
a
 
 (Fig. 3 B) may reflect
elevated IFN-
 
g
 
 production in these mice resulting from
protracted exposure to infection.
 
TNFR KO Mice Are Highly Susceptible to T. muris Infec-
tion.
 
As anti–TNF-
 
a
 
 treatment blocked protection in
C57BL/6 mice, we investigated the kinetics of infection in
mice completely deficient in TNFR signaling. We consis-
tently found that TNFR KO mice were highly susceptible
to 
 
T
 
.
 
 muris
 
 and unable to expel worms by day 35 p.i. (Fig.
4 A). Previous data have shown that mature worms (day 32
p.i.) can promote their own survival and can only be ex-
pelled through drug intervention after this time point (4).
WT mice began worm expulsion between days 10 and 18
p.i., and had completely cleared infection by day 22 (Fig. 4
B). Surprisingly, analysis of Ag-specific cytokine produc-
tion after restimulation of mesenteric lymph node cells
showed that TNFR KO mice made little or no Th2 cyto-
kines, whereas WT mice made a strong Th2 response
(characteristic of resistant strains [4, 7, 22]) with high levels
 
of IL-4, IL-5, IL-9, and IL-13 at day 18 p.i. (Fig. 5). How-
ever, KO mice produced higher levels of Ag-specific IFN-g
(KO, 221.32 6 121.17 U/ml; WT, 153.5 6 50.0 U/ml)
and IL-12 (KO, 585.51 6 139.09 ng/ml; WT, 123.03 6
103.38 ng/ml) after restimulation of mesenteric lymph
node cells.
Parasite-specific IgG isotype responses at day 35 p.i. re-
flected the resistant and susceptible phenotype of WT and
TNFR KO mice and the polarized Th response observed.
WT mice made high levels of IgG1 (Fig. 6 A) and rela-
tively low levels of IgG2a (Fig. 6 B) typical of resistant
mice. TNFR KO mice made lower IgG1 responses and
high levels of IgG2a (Fig. 6). The higher IgG2a response
generated in KO mice supported the elevated Th1 cyto-
kine levels observed in the absence of TNFR signaling. This
Figure 1. Mean worm burden 6 SEM in C57BL/6 mice treated with
either PBS, anti–TNF-a, or control Ig. Mice were infected on day 0 with
200 T. muris eggs and treated intraperitoneally with 2 mg mAb every 3 d
between days 7 and 19 p.i. Worm burdens from four mice per group
were determined on days 21 (A) and 35 (B). *Significantly higher worm
burden than control treated mice (P , 0.05).
Figure 2. Cytokine production from T. muris–infected C57BL/6 mice
after treatment with PBS, anti–TNF-a, or control Ig. Mesenteric lymph
node cells were removed on day 21 p.i., stimulated in vitro with 50 mg T.
muris Ag for 24 h, and supernatants were analyzed by sandwich ELISA for
the presence of IL-4 (A), IL-5 (B), IL-9 (C), and IL-13 (D). Results rep-
resent the mean values of four mice per group 6 SEM. *Significantly
lower than control treated groups (P , 0.05).956 Regulation of Th2 Cytokine Responses by TNF-a
is in accordance with previous observations in other sus-
ceptible strains that produced predominantly Th1 cytokines
and high levels of IgG2a (4–7).
IL-13–mediated Expulsion of T. muris Is Dependent on
TNF-a. We have previously shown that IL-13 is directly
involved in expulsion of T. muris, as IL-13 KO mice were
unable to clear infection despite generating equivalent par-
asite-specific Th2 responses to WT mice at day 21 p.i. (7).
Subsequent studies have also found that expulsion of T.
muris in female BALB/c IL-4 KO mice is IL-13 dependent.
In the absence of IL-4, protection is almost completely ab-
rogated by blockade of IL-13 using a soluble IL-13R fusion
protein (Bancroft, A.J., manuscript in preparation). To in-
vestigate whether this IL-13–mediated expulsion is also de-
pendent on TNF-a, infected female BALB/c IL-4 KO
mice were treated with 2 mg of anti–TNF-a mAb or rat
IgG intraperitoneally every 3 d between days 7 and 28 p.i.
Blockade of TNF-a in female BALB/c IL-4 KO mice
significantly prevented worm expulsion (Fig. 7 C). In ac-
cordance with previously unpublished data, in control
treated IL-4 KO mice worm expulsion was initiated
around day 22 p.i. (Fig. 7 B), and approximately 60% of
worms were cleared by day 35 p.i. (Fig. 7 C). Ag-specific
cytokine production by mesenteric lymph node cells at day
18 p.i. showed comparable Th2 responses in the different
treatment groups (Fig. 8), although IL-9 and IL-13 produc-
tion was lower in anti–TNF-a treated mice than in the
control Ig group (primarily as a result of the variability ob-
served in this group; Fig. 8, B and C). No difference in the
IgG1 response was observed between anti–TNF-a and
control treated groups (data not shown), supporting the hy-
pothesis that TNF-a blockade did not alter the generation
of Th2 responses, but may be critical at the effector stage
in the intestine. Comparable and relatively high IgG2a
responses were observed in all groups (data not shown), re-
flecting the production of Th1 cytokines as previously re-
ported in T. muris–infected C57BL/6 IL-4 KO mice (7).
Administration of TNF-a Enhances IL-13–mediated Expul-
sion of T. muris. Previous experiments have revealed a sex
difference in resistance to T. muris in BALB/c IL-4 KO
mice (Bancroft, A.J., and D. Artis, unpublished observa-
tions). We have now confirmed these data demonstrating
that female mice produce higher parasite-specific Th2 cy-
Figure 3. Ag-specific IgG isotype responses from naive (e) and T.
muris–infected C57BL/6 mice after treatment with PBS (m), anti–TNF-a
(d), or control Ig (j). Serum was collected from naive and infected mice
at day 35 p.i. and assayed by capture ELISA for the presence of IgG1 (A)
and IgG2a (B). Results represent the mean of four mice per group 6 SEM.
Figure 4. Mean worm burden 6 SEM in TNFR KO (A) and C57BL/6 3
129 WT (B) mice on various days after infection. Mice were infected on
day 0 with 200 T. muris eggs, and worm burden was assessed from four to
six mice per group. *Significantly lower worm burden than KO mice at
corresponding time point (P , 0.05).957 Artis et al.
tokines (IL-5, IL-9, and IL-13) than males (compare Fig. 8
with Table II) and elevated IgG1 responses during infec-
tion (data not shown). Therefore, female IL-4 KO mice
expel worms around day 35 p.i., whereas males are unable
to do so. To investigate whether elevation of TNF-a levels
in vivo could promote a resistant phenotype in male
BALB/c IL-4 KO mice, 2 mg of TNF-a was administered
intraperitoneally to infected mice daily between days 10
and 24 p.i., and infection outcome was monitored at days
21 and 35 p.i.
Administration of TNF-a to male BALB/c IL-4 KO
mice considerably increased worm expulsion by day 35
p.i., with 43% of worms cleared in TNF-a–treated mice
compared with no reduction in worm burden in the con-
trol group at day 35 p.i. (Table I; P , 0.05). (TNF-a treat-
ment did not have any obvious detrimental effects on the
general health of the animals.) Interestingly, treatment with
TNF-a did not alter the production of IL-5, IL-9, or IL-13
after in vitro restimulation with ES Ag (Table II), suggest-
ing again that TNF-a may potentiate the effects of Th2 cy-
tokines (in this case IL-13) rather than enhance their pro-
duction. In addition, no difference in IgG1 production was
observed between TNF-a and control treated mice al-
though higher IgG2a production was observed in TNF-a–
treated mice, reflecting higher IFN-g production (data not
shown). Administration of TNF-a to male IL-4 KO mice
conferred a similar rate of worm expulsion (Table II) to
that observed in female mice (Fig. 7), suggesting that im-
paired protection in male mice may be due to reduced lev-
els of TNF-a during infection. However, analysis of TNF-a
Figure 5. Cytokine production from T. muris–infected TNFR KO and
C57BL/6 3 129 WT mice. Mesenteric lymph node cells were removed
on day 18 p.i., stimulated in vitro with 50 mg T. muris Ag for 24 h, and
supernatants were analyzed by sandwich ELISA for the presence of IL-4
(A), IL-5 (B), IL-9 (C), and IL-13 (D). Results represent the mean values
of four to six mice per group 6 SEM. *Significantly lower than WT val-
ues (P , 0.05).
Figure 6. Ag-specific IgG isotype responses from T. muris–infected
TNFR KO (d) and C57BL/6 3 129 WT (j) mice (naive KO [e] and na-
ive WT [1]). Serum was collected from naive and infected mice at day 35
p.i. and assayed by capture ELISA for the presence of IgG1 (A) and IgG2a
(B). Results represent the mean of four to six mice per group 6 SEM.958 Regulation of Th2 Cytokine Responses by TNF-a
production after Ag-specific in vitro restimulation of me-
senteric lymph node cells showed no significant difference
between male and female mice (Table III). Therefore, im-
paired clearance of infection in male mice is more likely to
be due to lower Th2 responses compared with females
(Fig. 8, and Table II) rather than a defect in TNF-a pro-
duction. Thus, although there is no inherent difference be-
tween male and female IL-4 KO mice in the production of
TNF-a, administration of this cytokine is able to induce a
resistant phenotype in male mice without a significant ele-
vation in parasite-specific Th2 responses.
Discussion
Previous studies have shown that immune-mediated ex-
pulsion of the intestinal helminth T. muris is dependent on
IL-4 and IL-13 (5, 7). The results presented here provide
the first demonstration of a critical role for TNF-a in host
protection against an intestinal helminth infection and ex-
tend our understanding of the role of TNF-a as an essential
component of Th2 cell–mediated effector responses. TNF-a
is known to be a key mediator of pathogenesis in a broad
range of infectious, inflammatory, and autoimmune dis-
eases (for a review, see reference 26), although few studies
Figure 7. Mean worm burden 6 SEM in female BALB/c IL-4 KO
mice treated with either anti–TNF-a (black bars), control Ig (stippled
bars), or PBS (striped bars). Mice were infected on day 0 with 200 T.
muris eggs and treated intraperitoneally with 2 mg mAb every 3 d be-
tween days 7 and 28 p.i. Worm burdens from four mice per group were
determined on days 18, 22, and 35 p.i. *Significantly lower worm burden
than anti–TNF-a treated groups (P , 0.05).
Figure 8. Cytokine production from T. muris–infected female BALB/c IL-4 KO mice after treatment with anti–TNF-a (black bars), control Ig (stip-
pled bars), or PBS (striped bars). Mesenteric lymph node cells were removed on day 18 p.i., stimulated in vitro with 50 mg T. muris Ag for 24 h, and super-
natants were analyzed by sandwich ELISA for the presence of IL-5 (A), IL-9 (B), and IL-13 (C). Results represent the mean values from four mice per
group 6 SEM. *Significantly lower than control treated groups (P , 0.05).
Table I. Mean Worm Burden (6 SEM) in Male BALB/c IL-4 
KO Mice after Administration of TNF-a
Mean worm burden (6 SEM)
Day 21 Day 35
Infected 1 TNF-a 100.75 (6 6.92) 57.0 (6 20.59)*
Infected 1 PBS 96.0 (6 4.97) 105.0 (6 20.57)
Male BALB/c IL-4 KO mice were infected with 200 T. muris eggs on
day 0 and treated intraperitoneally with either 2 mg of TNF-a or an
equal volume of PBS daily between days 10 and 24 p.i. Worm burdens
were assessed on days 21 and 35 p.i. Results represent the mean values
of four animals (6 SEM) per group.
*Significantly lower worm burden than in PBS-treated mice (P  ,
0.05).959 Artis et al.
have investigated the role of this prototypic inflammatory
cytokine in the regulation of immune responses dominated
by Th2 cytokines. The role of TNF-a in the pathogenesis
of predominantly Th1-mediated inflammation, including
collagen-induced arthritis (27), autoimmune encephalomy-
elitis (28), and intestinal inflammation (29, 30), is well
characterized. Our results extend these observations and
identify a novel role for TNF-a in the regulation of Th2
cell–mediated protection during helminth infection.
It is significant that immunodepletion of TNF-a in
C57BL/6 and BALB/c IL-4 KO mice showed little or no
reduction in the magnitude of Ag-specific Th2 cytokine
production and IgG1 responses during infection, despite
blocking worm expulsion. This demonstrated that block-
ade of TNF-a had little effect on the initiation of Th2 re-
sponses in the draining lymph node. Preliminary analysis of
intestinal mast cell hyperplasia (which is under the control
of Th2 cytokines) during infection in C57BL/6 mice
showed a depressed mastocytosis after anti–TNF-a treat-
ment (data not shown). This supports the hypothesis that
although the magnitude of the Th2 response in the drain-
ing lymph node is unaltered, in the intestinal microenvi-
ronment the Th2 response is impaired, implicating a role
for TNF-a in regulation of effector function. Previous ex-
periments have shown that in vivo elevation of IL-9 en-
hances resistance to T. muris (31), and after depletion of
TNF-a in infected C57BL/6 and female IL-4 KO mice
the depressed production of IL-9 may be important in pre-
venting normal expulsion (although it is clear that mast
cells are not important in host protection [32]).
TNF-a is known to regulate expression of a range of cell
adhesion molecules on vascular endothelium (33, 34) and
leukocytes (35) and to control the expression of chemoat-
tractant cytokines (36). In addition, TNF-a has been
shown to be necessary for homing of Th2 cells to the site
of allergic inflammation (17). Thus, ongoing studies are ad-
dressing leukocyte homing and recirculation to the intes-
tine during infection in the presence and absence of TNF-a.
TNF-a is a pleiotropic cytokine, and the mechanisms of
regulating host protection to T. muris may not be through
the recruitment of inflammatory cells, but rather through
amplification of the existing Th2 response. Certainly,
TNF-a has been shown to enhance Th2 cell–mediated
phenomena in other systems, including pathogenesis of al-
lergic inflammation in the gastric mucosa (37), Schistosoma
mansoni egg–induced granuloma formation (38, 39), and
airway hyperresponsiveness (17).
A role for TNF-a in amplifying effector function of Th2
cytokines is recapitulated by our studies in which at least
partial protection against T. muris can be conferred on nor-
mally susceptible male BALB/c IL-4 KO mice after admin-
istration of TNF-a. Comparison between the magnitude
of the Th2 response mounted in male and female BALB/c
IL-4 KO mice supports previously unpublished data dem-
onstrating a Th2 bias in females and enhanced protection.
Furthermore, it is clear that sex differences in host protec-
tion are not due to lower TNF-a production in male mice
after infection. That enhancing in vivo levels of TNF-a in
male IL-4 KO mice increased worm expulsion at day 35
p.i. to levels similar to those observed in female mice
(without altering the levels of Th2 cytokines produced)
supports the hypothesis that TNF-a is acting downstream
of Th2 cell differentiation and is potentiating the protective
effects of Th2 cytokines in male mice. Whether TNF-a
administration can enhance IL-13–mediated phenomena in
other systems such as airway inflammation (15, 16), S. man-
soni egg–induced pulmonary granuloma (40), and resistance
to Nippostrongylus brasiliensis infection (41) remains to be
determined.
The development of chronic infection in mice deficient
in TNFR p55 and p75 provides the first characterization of
intestinal helminth infection in these mice. The inability of
TNFR KO mice to expel T. muris may reflect a similar im-
pairment of Th2 cell–mediated effector function as sug-
gested above. However, we were unable to detect any sig-
nificant Th2 cytokines after restimulation of mesenteric
lymph node cells in these mice, suggesting that the absence
of TNF-a function at the initiation of infection in TNFR
Table II.  Th2 Cytokine Production (6 SEM) by Ag-stimulated 
Mesenteric Lymph Node Cells from Male BALB-c IL-4 KO Mice at 
Day 21 p.i.
Naive* Infected 1 PBS Infected 1 TNF
IL-5 (U/ml) 2.072 2.744 (6 0.25) 2.52 (6 1.03)
IL-9 (U/ml) 2.291 7.84 (6 3.28) 10.63 (6 2.05)
IL-13 (pg/ml) 5.892 231.44 (6 44.05) 278.45 (6 38.87)
Male BALB/c IL-4 KO mice were infected with 200 T. muris eggs on
day 0 and treated intraperitoneally with either 2 mg of TNF-a or an
equal volume of PBS daily between days 10 and 24 p.i. Mesenteric
lymph node cells were taken on day 21 p.i., restimulated in vitro, and
supernatants were assayed for cytokine by ELISA. Results represent the
mean values (6 SEM) of four animals per group.
*Represents data from pooled mesenteric lymph node cells.
Table III. TNF-a Production (6 SEM) by Ag-stimulated 
Mesenteric Lymph Node Cells from Male and Female BALB/c IL-4 
KO Mice at Day 18 p.i.
Naive* Infected
pg/ml pg/ml
Male 103.19 307.58 6 43.68
Female 139.23 236.54 6 50.53
Male and female BALB/c IL-4 KO mice were infected with 200 T. muris
eggs on day 0, and mesenteric lymph node cells were restimulated in vitro
with parasite antigen. Supernatants were assayed for cytokine by ELISA.
Results represent the mean values (6 SEM) of four animals per group.
*Represents data from pooled mesenteric lymph node cells.960 Regulation of Th2 Cytokine Responses by TNF-a
KO mice had a profoundly different effect (i.e., impairing
initiation of a Th2 response) than depletion of TNF-a later
in infection (see above). Mice deficient in either or both
p55 and p75 have been shown to be resistant to lethal
shock induced by LPS (42), have attenuated responses to
cerebral malaria (43), and were highly susceptible to intra-
cellular bacterial (42, 44, 45) and protozoan infections (46).
TNFR KO mice have also revealed a novel role for these
receptors in lymphoid tissue organogenesis and morpho-
genesis with the reported absence of B cell follicles, germi-
nal center formation, and follicular dendritic cell networks
(for reviews, see references 47 and 48). Our results demon-
strate no impairment of immune responsiveness per se dur-
ing T. muris infection, with polarized Ag-specific Th1 cy-
tokine production and strong parasite-specific IgG isotype
responses detected at day 35 p.i. It has been suggested that
IgG isotype switching in TNFR KO mice is normal (49),
and given that expulsion of T. muris can occur in the ab-
sence of antibody (23), we feel this is not the basis of sus-
ceptibility to infection in these mice. However, we cannot
rule out impaired or altered Ag sampling, processing, and
presentation in TNFR KO mice, given the reported ab-
sence of Peyer’s patches in TNFR KO mice (50) and the
suggested role for TNF-a in the maturation of dendritic
cell function (51, 52) and migration to the draining lymph
node (53). Such alterations in initiation of the response may
result in the polarized Th1 response observed after infec-
tion, suggesting a potentially critical role for TNF-a in re-
sponse induction. (LT-a is also known to bind TNFR
with equal affinity and kinetics to TNF-a [54], and may
play a role in host protection.)
In this context, there are several conflicting studies on
the role of TNF-a in autoimmune diseases such as insulitis
(55, 56) with the outcome of TNF-a administration and
blockade clearly dependent on the cytokine dose, duration
of exposure, and site of expression (57), and similar pro-
cesses may be operating in our system. The data presented
here support the hypothesis that TNF-a, when adminis-
tered or blocked after the first week of infection (and coin-
cident with the generation of a Th2 response), has a clear
effect on host protection without altering the magnitude of
the Th2 response, while the absence of TNF function from
day 0 (in TNFR KO mice) inhibits the induction of Th2
responses. However, the exact molecular and cellular
mechanisms through which TNF-a mediates its protective
effects remain to be elucidated. For instance, does TNF-a
act on lymphocyte populations to augment Th2 effector
cell responses (58), on APC function, or on multiple cell
types derived from a nonlymphoid lineage? And what con-
tribution do the independently regulated and functionally
distinct p55 and p75 receptors make to host protection?
That administration and blockade of TNF-a can modu-
late infection outcome without altering the production of
Th2 cytokines suggests a role for TNF-a in regulating Th2
effector function. An attractive hypothesis is that TNF-a
functions through regulation of IL-4 and IL-13 receptor
expression on cells in the intestinal microenvironment, a
function that has been observed in human endothelial cells
(59). However, it is clear that we have identified a novel
role for TNF-a in regulating Th2 cytokine responses in
the intestine, which has a significant effect on protective
immunity to helminth infection. As such, these results ex-
tend our understanding of the complex interplay of the cy-
tokine network and have significant implications for the
design of rational therapies against helminth infection and
allergic reactions in the gut and at other mucosal sites.
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